John J Mariani1,2, Robert J Malcolm3, Agnieszka K Mamczur1, Jean C Choi4, Ronald Brady5, Edward Nunes1,2, Frances R Levin1,2. 1. a Division on Substance Abuse , New York State Psychiatric Institute , New York , NY , USA. 2. b Department of Psychiatry , College of Physicians and Surgeons of Columbia University , New York , NY , USA. 3. c Medical University of South Carolina , Charleston , SC , USA. 4. d Division of Biostatistics , New York State Psychiatric Institute , New York , NY , USA. 5. e NarcoFreedom , Bronx , NY , USA.
Abstract
BACKGROUND:Benzodiazepine use disorders are a common clinical problem among methadone maintenance treatment patients and have adverse effects on clinical outcomes. OBJECTIVES: To evaluate gabapentin for the outpatient treatment of benzodiazepineabuse or dependence in methadone maintenance patients. METHODS:Participants (n = 19) using benzodiazepines at least 4 days per week were enrolled into an 8-week randomized double-blind placebo-controlled outpatient pilot trial. All participants received a manual-guided supportive psychotherapy aimed to promote abstinence. Study medication was titrated over a 2-week period to a maximum dose of gabapentin 1200 mg or placebo three times a day. Benzodiazepine use was assessed using urine toxicology confirmed self-report. Benzodiazepines were not provided as part of study participation; participants were provided guidance to gradually reduce benzodiazepine intake. RESULTS:Sixteen participants had post-randomization data for analysis. Retention at week eight was 50%. The mean dose of gabapentin achieved by titration was 2666 mg/day (SD = ± 1446). There were no significant between group differences on benzodiazepine use outcomes (amount benzodiazepine per day [Mann-Whitney U = 27, p = 0.745], abstinent days per week [U = 28, p = 0.811]) and Clinical Instrument Withdrawal Assessment (CIWA)-benzodiazepines scale (U = 29.0, p = 0.913). One participant in the gabapentin group discontinued study medication because of peripheral edema. Two participants in the placebo group requested admission for inpatient detoxification treatment. CONCLUSION: In outpatient methadone-maintained patients with benzodiazepine use disorder, gabapentin did significantly decrease benzodiazepine use relative to placebo. The small sample recruited for this trial may have limited the ability to detect a group difference.
RCT Entities:
BACKGROUND:Benzodiazepine use disorders are a common clinical problem among methadone maintenance treatment patients and have adverse effects on clinical outcomes. OBJECTIVES: To evaluate gabapentin for the outpatient treatment of benzodiazepine abuse or dependence in methadone maintenance patients. METHODS:Participants (n = 19) using benzodiazepines at least 4 days per week were enrolled into an 8-week randomized double-blind placebo-controlled outpatient pilot trial. All participants received a manual-guided supportive psychotherapy aimed to promote abstinence. Study medication was titrated over a 2-week period to a maximum dose of gabapentin 1200 mg or placebo three times a day. Benzodiazepine use was assessed using urine toxicology confirmed self-report. Benzodiazepines were not provided as part of study participation; participants were provided guidance to gradually reduce benzodiazepine intake. RESULTS: Sixteen participants had post-randomization data for analysis. Retention at week eight was 50%. The mean dose of gabapentin achieved by titration was 2666 mg/day (SD = ± 1446). There were no significant between group differences on benzodiazepine use outcomes (amount benzodiazepine per day [Mann-Whitney U = 27, p = 0.745], abstinent days per week [U = 28, p = 0.811]) and Clinical Instrument Withdrawal Assessment (CIWA)-benzodiazepines scale (U = 29.0, p = 0.913). One participant in the gabapentin group discontinued study medication because of peripheral edema. Two participants in the placebo group requested admission for inpatient detoxification treatment. CONCLUSION: In outpatientmethadone-maintained patients with benzodiazepine use disorder, gabapentin did significantly decrease benzodiazepine use relative to placebo. The small sample recruited for this trial may have limited the ability to detect a group difference.
Authors: M J McLean; M J Morrell; L J Willmore; M D Privitera; R E Faught; G L Holmes; L Magnus-Miller; P Bernstein; A Rose-Legatt Journal: Epilepsia Date: 1999-07 Impact factor: 5.864
Authors: Francisco José Eiroa-Orosa; Christian Haasen; Uwe Verthein; Christoph Dilg; Ingo Schäfer; Jens Reimer Journal: Drug Alcohol Depend Date: 2010-08-12 Impact factor: 4.492
Authors: Kevin W Chen; Christine C Berger; Darlene P Forde; Christopher D'Adamo; Eric Weintraub; Devang Gandhi Journal: BMC Psychiatry Date: 2011-05-19 Impact factor: 3.630
Authors: John J Mariani; Martina Pavlicova; Cale Basaraba; Agnieszka Mamczur-Fuller; Daniel J Brooks; Adam Bisaga; Kenneth M Carpenter; Edward V Nunes; Frances R Levin Journal: Alcohol Clin Exp Res Date: 2021-07-05 Impact factor: 3.928
Authors: K Blum; M Gold; E J Modestino; D Baron; B Boyett; D Siwicki; L Lott; A Podesta; A K Roy; M Hauser; B W Downs; R D Badgaiyan Journal: J Syst Integr Neurosci Date: 2018-05-03